Thelansis’s "Moderate to Severe Palmoplantar Pustulosis (PPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Palmoplantar Pustulosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Moderate to severe palmoplantar pustulosis (PPP) is a debilitating, chronic inflammatory skin disorder characterized by dense sterile pustules, erythema, and painful fissuring on the palms and soles. At this severity, PPP significantly impairs mobility and hand function and often proves resistant to first‑line topical corticosteroids and vitamin D analogs. The pathogenesis involves immune dysregulation with IL‑36 signaling and downstream cytokines such as IL‑8, driving marked neutrophil recruitment to the acrosyringium. Management requires systemic therapy, including oral retinoids (acitretin), cyclosporine, or methotrexate, while biologics targeting IL‑17, IL‑23, or IL‑36 pathways have emerged as key options for refractory cases. Despite therapeutic advances, PPP remains a relapsing condition with profound impact on quality of life, underscoring the need for personalized and long‑term treatment strategies.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Moderate to Severe Palmoplantar Pustulosis (PPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Moderate to Severe Palmoplantar Pustulosis (PPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.